News | October 16, 2007

Sirolimus Stents Exacerbate Endothelial Injury after MI

October 17, 2007 - Compared to bare metal stents, in patients with acute myocardial infarction, sirolimus-eluting stent (SES) implantation aggravates endothelial vasomotor dysfunction in the infarct-related coronary artery, Japanese researchers report in the October 2nd issue of the Journal of the American College of Cardiology.

Kiyotaka Kugiyama, M.D., and colleagues at the University of Yamanashi, Chuo City note that drug-eluting stents reduce restenosis rates and revascularization but may impair recovery from reperfusion-induced endothelial injury.

To investigate, the researchers studied 29 patients with a first acute MI of the left anterior descending coronary artery (LAD). Thirteen had successful reperfusion therapy using an SES and the remaining 16 also had successful therapy employing a bare metal stent.

At two weeks, following intracoronary infusion of acetylcholine, the epicardial coronary artery became more severely restricted in the SES than the bare metal group. SES patients also had a lower increase in coronary blood flow in response to the agent.

In addition, levels of vascular endothelial growth factor (VEGF) in the anterior interventricular vein were significantly lower than in the aortic root in SES patients. This was not the case in the bare metal group.

The researchers stress that larger randomized studies are needed to confirm these findings. However, "these findings suggest that SES implantation may decrease the release of VEGF from the myocardial region supplied by the LAD, which may play a possible role in endothelial vasomotor dysfunction in infarct-related coronary arteries treated with SES."

Reference: J Am Coll Cardiol 2007;50:1305-1309

Source: Reuters

Related Content

Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
Onyx DES 2.0 mm stent meets primary endpoints in small vessels
News | June 12, 2017
June 12, 2017 – The Medtronic Resolute Onyx Drug-Eluting Stent (DES) met its primary endpoint of target lesion failur
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Sponsored Content | Videos | Stents Drug Eluting| May 01, 2017
This video, provided by Medtronic, demonstrates the Resolute Onyx coronary stent.
Biosensors, BioFreedom drug-coated stent, LEADERS FREE II IDE trial, first patient, U.S. pivotal study
News | Stents Drug Eluting| March 03, 2017
Biosensors International Group Ltd. announced in February enrollment of the first patient in LEADERS FREE II, its new...
CeloNova Cobra Pzf stent
Technology | Stents| March 02, 2017
March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc.
Synergy stent, abluminal polymer DES, bioresorbable polymer DES, bioresorbable polymer metallic stent

The Synergy stent is the first FDA cleared drug-eluting stent to use a bioresorbable polymer drug carrier. When the polymer dissolves after about four months, the devices become a bare metal stent. The technology is supposed to reduce the rate of late stent thrombosis due to vessel inflammation caused by durable polymers.

Feature | Stents Bioresorbable| January 17, 2017 | Dave Fornell
One of the big advancements in drug-eluting stent (DES) technology has been the development of bioresorbable polymers
OCT, intravascular imaging, stent, good stent apposition on vessel wall, TRANSFORM-OCT study

An OCT image showing good stent strut apposition against the vessel wall.

News | Stents| January 13, 2017
January 13, 2017 — Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
EXCEL Trial, TCT 2016, drug-eluting stents, CABG, surgery left main heart disease, LMCAD

Gregg W. Stone, M.D., presenting the EXCEL data at TCT 2016 during a standing room only late-breaking trial session.

Feature | Stents| January 12, 2017 | Dave Fornell
The biggest news from the 2016 Transcatheter Cardiovascular Therapeutics (TCT) meeting this past fall was the results
Overlay Init